Related Experiment Video
Updated: Feb 26, 2026
08:29
Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA
Published on: February 1, 2019
10.7K
Safe and Highly Efficient Lipid-Pro-Dexamethasone Nanoparticles for mRNA Delivery and Base Editing.
Yan Zong1, Haiping Zhong2,3, Yuqing Wang1
1Department of Biomedical Engineering, College of Future Technology, Peking University, Beijing 100871, China.
Journal of the American Chemical Society
|February 24, 2026
Summary
The new Safe and Highly Efficient Lipid-pro-dexamethasone (SHIELD) LNP platform reduces inflammation and effectively delivers mRNA, offering a promising advancement for mRNA therapies.
Area of Science:
- Biotechnology
- Drug Delivery
- Immunology
Background:
- mRNA lipid nanoparticles (LNPs) exhibit inherent immunogenicity, limiting their therapeutic use.
- Developing safer and more effective mRNA delivery systems is crucial for advancing disease treatments.
Purpose of the Study:
- To create an innovative mRNA delivery platform with reduced immunogenicity.
- To establish the Safe and Highly Efficient Lipid-pro-dexamethasone (SHIELD) LNP platform using novel dexamethasone prodrug ionizable lipids (DPILs).
Main Methods:
- Synthesized and evaluated novel dexamethasone prodrug ionizable lipids (DPILs).
- Formulated SHIELD LNPs and assessed their immunogenicity and mRNA delivery efficiency compared to SM-102 LNPs.
- Tested SHIELD LNP universality across different organ-targeting formulations.
- Investigated SHIELD LNP applications in gene editing and protein replacement therapies.
Main Results:
- The lead SHIELD LNP formulation (DEX-SPM-CP10) significantly reduced proinflammatory cytokines.
- SHIELD LNPs demonstrated mRNA delivery efficiency comparable to FDA-approved SM-102 LNPs.
- The SHIELD platform showed broad applicability, reducing inflammation and enhancing mRNA expression in various organs.
- Successful application in gene editing and protein replacement therapies with minimal immunogenicity.
Conclusions:
- The SHIELD LNP platform provides a safe and effective method for mRNA delivery.
- This platform has the potential to overcome LNP immunogenicity challenges and expand mRNA-based therapeutic applications.
